ReShape Cash vs Total Liab Analysis
RSLS Stock | USD 5.68 0.07 1.22% |
ReShape Lifesciences financial indicator trend analysis is much more than just breaking down ReShape Lifesciences prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether ReShape Lifesciences is a good investment. Please check the relationship between ReShape Lifesciences Cash and its Total Liab accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ReShape Lifesciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more information on how to buy ReShape Stock please use our How to Invest in ReShape Lifesciences guide.
Cash vs Total Liab
Cash vs Total Liab Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of ReShape Lifesciences Cash account and Total Liab. At this time, the significance of the direction appears to have almost no relationship.
The correlation between ReShape Lifesciences' Cash and Total Liab is 0.1. Overlapping area represents the amount of variation of Cash that can explain the historical movement of Total Liab in the same time period over historical financial statements of ReShape Lifesciences, assuming nothing else is changed. The correlation between historical values of ReShape Lifesciences' Cash and Total Liab is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cash of ReShape Lifesciences are associated (or correlated) with its Total Liab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Liab has no effect on the direction of Cash i.e., ReShape Lifesciences' Cash and Total Liab go up and down completely randomly.
Correlation Coefficient | 0.1 |
Relationship Direction | Positive |
Relationship Strength | Insignificant |
Cash
Cash refers to the most liquid asset of ReShape Lifesciences, which is listed under current asset account on ReShape Lifesciences balance sheet and usually includes currency, coins, checking accounts, and not deposited checks received from ReShape Lifesciences customers. The amounts must be unrestricted with restricted cash listed in a different ReShape Lifesciences account. The total amount of money in the form of currency that a company has in its possession. This includes all bills, coins, and funds in bank accounts.Total Liab
The total amount of all liabilities that a company has, including both short-term and long-term liabilities.Most indicators from ReShape Lifesciences' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into ReShape Lifesciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ReShape Lifesciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more information on how to buy ReShape Stock please use our How to Invest in ReShape Lifesciences guide.At this time, ReShape Lifesciences' Selling General Administrative is comparatively stable compared to the past year. Enterprise Value Over EBITDA is likely to gain to 0.20 in 2024, whereas Tax Provision is likely to drop (36.8 K) in 2024.
ReShape Lifesciences fundamental ratios Correlations
Click cells to compare fundamentals
ReShape Lifesciences Account Relationship Matchups
High Positive Relationship
High Negative Relationship
ReShape Lifesciences fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 39.7M | 37.1M | 54.3M | 11.1M | 10.7M | 10.1M | |
Total Stockholder Equity | 24.1M | 14.5M | 46.1M | 3.7M | 6.7M | 6.3M | |
Retained Earnings | (493.2M) | (514.8M) | (576.8M) | (624.2M) | (635.6M) | (603.8M) | |
Other Assets | 99K | 46K | 1.5M | 102K | 117.3K | 111.4K | |
Common Stock Shares Outstanding | 31.4K | 26.0K | 3.8K | 7.3K | 102.7K | 128.9K | |
Liabilities And Stockholders Equity | 39.7M | 37.1M | 54.3M | 11.1M | 10.7M | 10.1M | |
Other Stockholder Equity | 517.3M | 529.4M | 622.4M | 627.9M | 642.3M | 323.4M | |
Total Liab | 15.6M | 22.6M | 8.2M | 7.5M | 4M | 3.8M | |
Short Long Term Debt Total | 3.0M | 9.5M | 279K | 171K | 262K | 248.9K | |
Other Current Liab | 5.6M | 7.2M | 3.2M | 5.1M | 1.8M | 3.3M | |
Total Current Liabilities | 10.4M | 11.6M | 7.3M | 7.5M | 3.8M | 6.0M | |
Property Plant And Equipment Net | 774K | 1.0M | 1.7M | 869K | 310K | 600.4K | |
Net Debt | (2.2M) | (2.5M) | (22.5M) | (3.7M) | (4.2M) | (4.4M) | |
Accounts Payable | 4.3M | 3.7M | 3.5M | 1.9M | 1.7M | 1.3M | |
Cash | 2.9M | 3.0M | 22.8M | 3.9M | 4.5M | 4.2M | |
Non Current Assets Total | 29.5M | 28.1M | 24.0M | 1.2M | 367K | 348.7K | |
Non Currrent Assets Other | 562.9K | 99K | 46K | 1.5M | 29K | 27.6K | |
Cash And Short Term Investments | 2.9M | 3.0M | 22.8M | 3.9M | 4.5M | 4.2M | |
Net Receivables | 4.1M | 2.6M | 2.8M | 2.2M | 1.7M | 997.2K | |
Non Current Liabilities Total | 5.2M | 11.0M | 855K | 2.6M | 223K | 211.9K | |
Other Current Assets | 1.7M | 1.1M | 1.4M | 265K | 437K | 415.2K | |
Property Plant And Equipment Gross | 774K | 1.0M | 1.7M | 1.2M | 400K | 618.1K | |
Total Current Assets | 10.1M | 8.9M | 30.3M | 9.9M | 10.3M | 16.2M | |
Accumulated Other Comprehensive Income | (8K) | (121K) | (92K) | (88K) | (79.2K) | (83.2K) | |
Short Term Debt | 291K | 314K | 558K | 342K | 222K | 210.9K | |
Common Stock | 8K | 6K | 18K | 1K | 23K | 21.9K | |
Property Plant Equipment | 16K | 584K | 1.7M | 869K | 782.1K | 565.6K | |
Other Liab | 6.2M | 4.7M | 1.6M | 855K | 983.3K | 934.1K | |
Current Deferred Revenue | 352K | 202K | 398K | 549K | 44K | 46.2K | |
Inventory | 1.3M | 2.2M | 3.0M | 3.6M | 3.7M | 3.9M | |
Net Tangible Assets | (4.6M) | (12.5M) | 25.2M | 3.4M | 3.1M | 4.0M | |
Retained Earnings Total Equity | (334.8M) | (419.0M) | (493.2M) | (514.8M) | (463.3M) | (486.5M) | |
Capital Surpluse | 410.8M | 450.6M | 517.3M | 529.4M | 608.8M | 386.1M | |
Deferred Long Term Liab | 5.3M | 1.8M | 702K | 615K | 707.3K | 929.9K | |
Intangible Assets | 28.7M | 27.0M | 20.8M | 260K | 299K | 284.1K |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for ReShape Stock Analysis
When running ReShape Lifesciences' price analysis, check to measure ReShape Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ReShape Lifesciences is operating at the current time. Most of ReShape Lifesciences' value examination focuses on studying past and present price action to predict the probability of ReShape Lifesciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ReShape Lifesciences' price. Additionally, you may evaluate how the addition of ReShape Lifesciences to your portfolios can decrease your overall portfolio volatility.